Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 723 JPY 7.59% Market Closed
Market Cap: 10.6B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
Inventory

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Perseus Proteomics Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
Inventory
ÂĄ4.4m
CAGR 3-Years
32%
CAGR 5-Years
13%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Inventory
ÂĄ3B
CAGR 3-Years
37%
CAGR 5-Years
33%
CAGR 10-Years
35%
PeptiDream Inc
TSE:4587
Inventory
ÂĄ2.8B
CAGR 3-Years
49%
CAGR 5-Years
52%
CAGR 10-Years
N/A
Takara Bio Inc
TSE:4974
Inventory
ÂĄ12.9B
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
11%
Pharma Foods International Co Ltd
TSE:2929
Inventory
ÂĄ6.7B
CAGR 3-Years
35%
CAGR 5-Years
45%
CAGR 10-Years
42%
C
Cuorips Inc
TSE:4894
Inventory
ÂĄ1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
10.3B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
719.16 JPY
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's Inventory?
Inventory
4.4m JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Inventory amounts to 4.4m JPY.

What is Perseus Proteomics Inc's Inventory growth rate?
Inventory CAGR 5Y
13%

Over the last year, the Inventory growth was 39%. The average annual Inventory growth rates for Perseus Proteomics Inc have been 32% over the past three years , 13% over the past five years .

Back to Top